Jialin Qu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jialin Qu has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Aijing Leng
Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, P. R. China
6 shared publications Cai Chen
Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China
6 shared publicationsXiaojie Li
Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China
6 shared publicationsAijing Leng
Department of Traditional Chinese Medicine, The First Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Dalian, 116011, China
5 shared publicationsYuankuan Jiang
Laboratory of Integrative Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian, China
5 shared publicationsJiahui Zhang
Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China
4 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in SSRN Electronic Journal
Ferroptosis-Based Therapeutic Strategies in Glioma: Mechanisms, Vulnerabilities, and Emerging Translational Opportunities
BackgroundGlioma remains difficult to treat because of diffuse infiltration, intratumoral heterogeneity, blood–brain barrier constraints and resistance to conventional therapy. Its hypoxic, metabolically reprogrammed and redox-adapted state creates vulnerabilities in iron metabolism, membrane lipid oxidation and antioxidant defense, making ferroptosis a potential therapeutic target.PurposeThis review provides a mechanism-oriented synthesis of ferroptosis regulation in glioma and evaluates therapeutic agents and strategies, with particular attention to natural products, traditional medicine-derived compounds, combination regimens and delivery platforms.Materials and methodsPubMed was searched for studies published from 1 January 2018 through 1 September 2026 using (“ferroptosis” OR “ferroptotic”) AND (“glioma” OR “glioblastoma” OR “GBM”). Of 677 records, 545 were excluded after title and abstract screening and 26 of 132 full-text reports were excluded. The remaining 106 eligible therapeutic studies were classified by their predominant ferroptosis-regulatory mechanisms and therapeutic modalities (Fig. 1).ResultsFerroptosis susceptibility in glioma is governed by labile iron accumulation, oxidation-prone phospholipid remodeling, lipid peroxide propagation and failure of antioxidant systems, particularly the System Xc−–GSH–GPX4 axis. Reported interventions promote iron-dependent oxidative stress, enhance lipid peroxidation, suppress GPX4- or NRF2-centered defenses, induce organelle-associated ferroptotic stress, or modulate the tumor microenvironment. In preclinical models, these approaches inhibited tumor growth, sensitized resistant cells and improved the spatial control of ferroptosis through targeted or stimuli-responsive delivery.ConclusionsFerroptosis is a promising but complex therapeutic vulnerability in glioma. Translation will require coordinated targeting of iron metabolism, lipid peroxidation and antioxidant defenses, together with improved brain penetration, tumor selectivity, neural safety, predictive biomarkers and rational combination strategies.
- 13 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFerroptosis-Based Therapeutic Strategies in Glioma: Mechanisms, Vulnerabilities, and Emerging Translational Opportunities
BackgroundGlioma remains difficult to treat because of diffuse infiltration, intratumoral heterogeneity, blood–brain barrier constraints and resistance to conventional therapy. Its hypoxic, metabolically reprogrammed and redox-adapted state creates vulnerabilities in iron metabolism, membrane lipid oxidation and antioxidant defense, making ferroptosis a potential therapeutic target.PurposeThis review provides a mechanism-oriented synthesis of ferroptosis regulation in glioma and evaluates therapeutic agents and strategies, with particular attention to natural products, traditional medicine-derived compounds, combination regimens and delivery platforms.Materials and methodsPubMed was searched for studies published from 1 January 2018 through 1 September 2026 using (“ferroptosis” OR “ferroptotic”) AND (“glioma” OR “glioblastoma” OR “GBM”). Of 677 records, 545 were excluded after title and abstract screening and 26 of 132 full-text reports were excluded. The remaining 106 eligible therapeutic studies were classified by their predominant ferroptosis-regulatory mechanisms and therapeutic modalities (Fig. 1).ResultsFerroptosis susceptibility in glioma is governed by labile iron accumulation, oxidation-prone phospholipid remodeling, lipid peroxide propagation and failure of antioxidant systems, particularly the System Xc−–GSH–GPX4 axis. Reported interventions promote iron-dependent oxidative stress, enhance lipid peroxidation, suppress GPX4- or NRF2-centered defenses, induce organelle-associated ferroptotic stress, or modulate the tumor microenvironment. In preclinical models, these approaches inhibited tumor growth, sensitized resistant cells and improved the spatial control of ferroptosis through targeted or stimuli-responsive delivery.ConclusionsFerroptosis is a promising but complex therapeutic vulnerability in glioma. Translation will require coordinated targeting of iron metabolism, lipid peroxidation and antioxidant defenses, together with improved brain penetration, tumor selectivity, neural safety, predictive biomarkers and rational combination strategies.
- Open Access
- 28 August 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 216
Correction: Brusatol ameliorates psoriatic dyslipidemia by targeting IL-1β to restore AMPK-mediated lipid homeostasis
- 28 August 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 216
Open AccessCorrection: Brusatol ameliorates psoriatic dyslipidemia by targeting IL-1β to restore AMPK-mediated lipid homeostasis
- 10 April 2026
- Published by Elsevier in Phytomedicine
- Vol. 156, 158177
Dictamnus dasycarpus Turcz. alleviates cholestatic liver injury: orchestrating tissue-divergent extracellular matrix remodeling across the gut-liver axis
- 10 April 2026
- Published by Elsevier in Phytomedicine
- Vol. 156, 158177
Dictamnus dasycarpus Turcz. alleviates cholestatic liver injury: orchestrating tissue-divergent extracellular matrix remodeling across the gut-liver axis
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-19
Qingyi Decoction Alleviates Alcoholic Pancreatitis by Improving Glycerolipid Homeostasis via the AMPK/SREBP-1c/PPARα Pathway
Background: Alcoholic pancreatitis (AP) is one of the most common types of acute pancreatitis, which is commonly accompanied by lipid metabolism disorders. Qingyi Decoction (QYD) is a traditional Chinese medicine formula for the treatment of acute and chronic pancreatitis in clinical. However, previous studies have mostly focused on its efficacy in biliary pancreatitis, leaving its efficacy and mechanistic underpinnings in AP largely unexplored and unreported. Methods: The mice with the AP model were established by intraperitoneal injections of a mixture of OA (150 mg/kg) and EtOH (1.35 g/kg) to evaluate the protective efficacy of QYD. The serum amylase, lipase, and pancreatic tissue myeloperoxidase (MPO) levels combined with histopathological analysis were used to evaluate the efficacy. Then, the differential lipids species associated with QYD treatment in improving AP were explored by a comprehensive lipidomics platform. Finally, the underlying mechanisms involving AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A signaling pathways were systematically examined using Western blot and RT-qPCR techniques to determine both protein and mRNA expression levels. Results: QYD administration significant reduced the serum levels of amylase and lipase as well as MPO activity in pancreatic tissue, and alleviated pancreatic tissue hispathological damage in AP mice. Additionally, QYD regulated the metabolism of lipids such as TAG, DAG and FFA, whose mechanism is closely associated with activation of AMPKα, leading to the concurrent suppression of downstream mediators in lipid synthesis (SREBP-1c, ACC1, and FASN) and enhancement of factors involved fatty acids β-oxidation (PPARα and CPT1A) at both proteins and mRNAs levels, respectively. Conclusion: The study demonstrates that QYD could protect AP through improving lipid metabolism disorder via AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A axis, which not only expands the clinical indications of QYD but also provides a novel therapeutic strategy and theoretical basis for the clinical treatment and drug development of AP. Plain Language Summary: Qingyi Decoction (QYD) significantly reduced serum amylase and lipase levels, decreased pancreatic MPO activity, and alleviated pancreatic tissue damage in mice with alcoholic pancreatitis (AP).Improving glycerolipid homeostasis participated in the protective regulation of QYD against AP.The protection of QYD was achieved via inhibiting lipid synthesis and promoting fatty acid β-oxidation through the AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A pathways.
- 1 March 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-19
Open AccessQingyi Decoction Alleviates Alcoholic Pancreatitis by Improving Glycerolipid Homeostasis via the AMPK/SREBP-1c/PPARα Pathway
Background: Alcoholic pancreatitis (AP) is one of the most common types of acute pancreatitis, which is commonly accompanied by lipid metabolism disorders. Qingyi Decoction (QYD) is a traditional Chinese medicine formula for the treatment of acute and chronic pancreatitis in clinical. However, previous studies have mostly focused on its efficacy in biliary pancreatitis, leaving its efficacy and mechanistic underpinnings in AP largely unexplored and unreported. Methods: The mice with the AP model were established by intraperitoneal injections of a mixture of OA (150 mg/kg) and EtOH (1.35 g/kg) to evaluate the protective efficacy of QYD. The serum amylase, lipase, and pancreatic tissue myeloperoxidase (MPO) levels combined with histopathological analysis were used to evaluate the efficacy. Then, the differential lipids species associated with QYD treatment in improving AP were explored by a comprehensive lipidomics platform. Finally, the underlying mechanisms involving AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A signaling pathways were systematically examined using Western blot and RT-qPCR techniques to determine both protein and mRNA expression levels. Results: QYD administration significant reduced the serum levels of amylase and lipase as well as MPO activity in pancreatic tissue, and alleviated pancreatic tissue hispathological damage in AP mice. Additionally, QYD regulated the metabolism of lipids such as TAG, DAG and FFA, whose mechanism is closely associated with activation of AMPKα, leading to the concurrent suppression of downstream mediators in lipid synthesis (SREBP-1c, ACC1, and FASN) and enhancement of factors involved fatty acids β-oxidation (PPARα and CPT1A) at both proteins and mRNAs levels, respectively. Conclusion: The study demonstrates that QYD could protect AP through improving lipid metabolism disorder via AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A axis, which not only expands the clinical indications of QYD but also provides a novel therapeutic strategy and theoretical basis for the clinical treatment and drug development of AP. Plain Language Summary: Qingyi Decoction (QYD) significantly reduced serum amylase and lipase levels, decreased pancreatic MPO activity, and alleviated pancreatic tissue damage in mice with alcoholic pancreatitis (AP).Improving glycerolipid homeostasis participated in the protective regulation of QYD against AP.The protection of QYD was achieved via inhibiting lipid synthesis and promoting fatty acid β-oxidation through the AMPK-mediated SREBP-1c/FASN and PPARα/CPT1A pathways.
- Open Access
- 8 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 18
Brusatol ameliorates psoriatic dyslipidemia by targeting IL-1β to restore AMPK-mediated lipid homeostasis
Background: Psoriasis-associated dyslipidemia presents as a critical comorbidity characterized by a self-perpetuating cycle of metabolic dysfunction and chronic inflammation. Current treatment paradigms lack the capacity to simultaneously modulate these interconnected pathological axes. Here we investigated the efficacy and mechanisms of brusatol (a natural quassinoid derived from Bruceae Fructus) against psoriatic dyslipidemia from the insight of restoring lipid homeostasis. Methods: The in vitro efficacy of brusatol was assessed in TNF-α-stimulated HaCaT keratinocytes by evaluating proliferation, apoptosis, and inflammatory responses. In vivo, its therapeutic activity and systemic toxicity were examined in an imiquimod-induced psoriatic mouse model using PASI scoring, histopathological analysis, serum biochemical markers (TC, TG, ALT, AST, Cre), inflammatory cytokines (TNF-α, IL-1β, IL-17A), and BBB-chip analysis. Integrated proteomics and lipidomics of skin tissue and serum revealed dysregulated pathways, and subsequent target engagement was confirmed via molecular docking, CETSA, and DARTS. Mechanistic investigations included IL-1β overexpression, Co-IP, GST pull-down and AMPK pathway analysis (Western blot, qPCR) was explored to delineate the regulatory mechanisms. Results: Brusatol dose-dependently suppresses proliferation and inflammatory mediator expression in TNF-α-induced HaCaT keratinocytes, ameliorates skin lesions and systemic dyslipidemia in mice, effectively normalizing serum TC and TG levels without inducing visceral organ toxicity. Further integrated omic analyses and subsequent target validation identified IL-1β as the direct target linking inflammatory signaling and lipid dysregulation. Mechanistic studies uncovered a novel IL-1β–AMPK physical interaction that sequesters AMPK in the cytoplasm. Brusatol disrupts this complex, facilitating AMPK nuclear translocation to suppress lipogenic regulators (SREBP-1c/FASN/ACC1) and potentiate β-oxidation pathways (PPARα/CPT1A), thereby restoring lipid homeostasis. Conclusion: Our findings not only establish brusatol as an effective agent for ameliorating psoriatic dyslipidemia, but also unveil a fundamental IL-1β–AMPK interaction that orchestrates inflammation-metabolism crosstalk. Graphical
- 8 January 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 18
Open AccessBrusatol ameliorates psoriatic dyslipidemia by targeting IL-1β to restore AMPK-mediated lipid homeostasis
Background: Psoriasis-associated dyslipidemia presents as a critical comorbidity characterized by a self-perpetuating cycle of metabolic dysfunction and chronic inflammation. Current treatment paradigms lack the capacity to simultaneously modulate these interconnected pathological axes. Here we investigated the efficacy and mechanisms of brusatol (a natural quassinoid derived from Bruceae Fructus) against psoriatic dyslipidemia from the insight of restoring lipid homeostasis. Methods: The in vitro efficacy of brusatol was assessed in TNF-α-stimulated HaCaT keratinocytes by evaluating proliferation, apoptosis, and inflammatory responses. In vivo, its therapeutic activity and systemic toxicity were examined in an imiquimod-induced psoriatic mouse model using PASI scoring, histopathological analysis, serum biochemical markers (TC, TG, ALT, AST, Cre), inflammatory cytokines (TNF-α, IL-1β, IL-17A), and BBB-chip analysis. Integrated proteomics and lipidomics of skin tissue and serum revealed dysregulated pathways, and subsequent target engagement was confirmed via molecular docking, CETSA, and DARTS. Mechanistic investigations included IL-1β overexpression, Co-IP, GST pull-down and AMPK pathway analysis (Western blot, qPCR) was explored to delineate the regulatory mechanisms. Results: Brusatol dose-dependently suppresses proliferation and inflammatory mediator expression in TNF-α-induced HaCaT keratinocytes, ameliorates skin lesions and systemic dyslipidemia in mice, effectively normalizing serum TC and TG levels without inducing visceral organ toxicity. Further integrated omic analyses and subsequent target validation identified IL-1β as the direct target linking inflammatory signaling and lipid dysregulation. Mechanistic studies uncovered a novel IL-1β–AMPK physical interaction that sequesters AMPK in the cytoplasm. Brusatol disrupts this complex, facilitating AMPK nuclear translocation to suppress lipogenic regulators (SREBP-1c/FASN/ACC1) and potentiate β-oxidation pathways (PPARα/CPT1A), thereby restoring lipid homeostasis. Conclusion: Our findings not only establish brusatol as an effective agent for ameliorating psoriatic dyslipidemia, but also unveil a fundamental IL-1β–AMPK interaction that orchestrates inflammation-metabolism crosstalk. Graphical
- Open Access
- 2 July 2025
- Published by Springer Nature in Chinese Medicine
- Vol. 20 (1) , 1-19
Aloe vera-derived extracellular vesicle-like particles suppress pancreatic carcinoma progression through triggering pyroptosis via ROS-GSDMD/E signaling pathway
Background: Pancreatic carcinoma (PC) remains one of the most aggressive malignancies that is often referred to as the “king of cancers” in clinic. Plant-derived extracellular vesicle-like particles (p-EVLP) has demonstrated broad-spectrum antitumor potential through their unique ability to effectively penetrate tumor microenvironments and deliver bioactive compounds. Aloe Vera is a tender and juicy plant with anti-tumor properties, while whether Aloe Vera-derived EVLP (AV-EVLP) can inhibit PC and what the underlying mechanism is still unclear. Methods: Two kinds of AV-EVLPs (EV-U and EV-P) were isolated from Aloe vera using comparative purification techniques. Their structure and composition characterization were performed using TEM, NTA and UHPLC-QTOFMS. In vitro experiments using Panc-1 cells included cytotoxicity, migration/invasion and cellular uptake assay were employed to investigate their tumor inhibition potential. In a Panc-1 xenograft mouse model, the therapeutic effects and systemic toxicity of EV-U were evaluated through tumor volume and weight, Ki67, TUNEL and histopathology examination. Mechanistic studies involved the levels of cellular ROS, IL-1β, IL-18 and the expression of caspase-1/3/7/9-GSDMD/E in both cell and tumor tissues were determined by ELISA, immunohistochemistry, Western blot and qRT-PCR. Results: EV-U and EV-P exhibited characteristic cup-shaped morphology with mean diameters 179.3 nm and 227.1 nm, respectively. At their respective IC50 concentrations, both effectively inhibit cell migration and invasion and increase ROS, LDH, IL-18, and IL-1β levels in Panc-1 cells. Comparably, EV-U exhibited better activity due to their fewer impurities and more uniform dispersion. Further in vivo experiments supported the effectiveness of EV-U in reducing tumor volume and weight without causing toxicity or immunogenicity. Mechanistically, the activation of pyroptosis through the caspase-1/3/7/9-GSDMD/E pathways contributed to its efficacy. Conclusion: AV-EVLP significantly inhibit pancreatic cancer progression by triggering mitochondrial ROS release through the activation of caspase-1/3/7/9-GSDMD/E-mediated pyroptosis. Graphic AV-EVLPs effectively inhibited the migration and invasion of Panc-1 cell and reduced tumor volume and weight in Panc-1 tumor-bearing mice, whose mechanism was related to triggering pyroptosis via ROS-GSDMD/E pathways.
- 2 July 2025
- Published by Springer Nature in Chinese Medicine
- Vol. 20 (1) , 1-19
Open AccessAloe vera-derived extracellular vesicle-like particles suppress pancreatic carcinoma progression through triggering pyroptosis via ROS-GSDMD/E signaling pathway
Background: Pancreatic carcinoma (PC) remains one of the most aggressive malignancies that is often referred to as the “king of cancers” in clinic. Plant-derived extracellular vesicle-like particles (p-EVLP) has demonstrated broad-spectrum antitumor potential through their unique ability to effectively penetrate tumor microenvironments and deliver bioactive compounds. Aloe Vera is a tender and juicy plant with anti-tumor properties, while whether Aloe Vera-derived EVLP (AV-EVLP) can inhibit PC and what the underlying mechanism is still unclear. Methods: Two kinds of AV-EVLPs (EV-U and EV-P) were isolated from Aloe vera using comparative purification techniques. Their structure and composition characterization were performed using TEM, NTA and UHPLC-QTOFMS. In vitro experiments using Panc-1 cells included cytotoxicity, migration/invasion and cellular uptake assay were employed to investigate their tumor inhibition potential. In a Panc-1 xenograft mouse model, the therapeutic effects and systemic toxicity of EV-U were evaluated through tumor volume and weight, Ki67, TUNEL and histopathology examination. Mechanistic studies involved the levels of cellular ROS, IL-1β, IL-18 and the expression of caspase-1/3/7/9-GSDMD/E in both cell and tumor tissues were determined by ELISA, immunohistochemistry, Western blot and qRT-PCR. Results: EV-U and EV-P exhibited characteristic cup-shaped morphology with mean diameters 179.3 nm and 227.1 nm, respectively. At their respective IC50 concentrations, both effectively inhibit cell migration and invasion and increase ROS, LDH, IL-18, and IL-1β levels in Panc-1 cells. Comparably, EV-U exhibited better activity due to their fewer impurities and more uniform dispersion. Further in vivo experiments supported the effectiveness of EV-U in reducing tumor volume and weight without causing toxicity or immunogenicity. Mechanistically, the activation of pyroptosis through the caspase-1/3/7/9-GSDMD/E pathways contributed to its efficacy. Conclusion: AV-EVLP significantly inhibit pancreatic cancer progression by triggering mitochondrial ROS release through the activation of caspase-1/3/7/9-GSDMD/E-mediated pyroptosis. Graphic AV-EVLPs effectively inhibited the migration and invasion of Panc-1 cell and reduced tumor volume and weight in Panc-1 tumor-bearing mice, whose mechanism was related to triggering pyroptosis via ROS-GSDMD/E pathways.
- 5 May 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 349, 119872
Animal-derived peptides from Traditional Chinese medicines: medicinal potential, mechanisms, and prospects
- 5 May 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 349, 119872
Animal-derived peptides from Traditional Chinese medicines: medicinal potential, mechanisms, and prospects
- 6 April 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 351, 119561
Violae Herba: A comprehensive review of the traditional uses, phytochemistry, pharmacology, quality control and clinical applications
- 6 April 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 351, 119561
Violae Herba: A comprehensive review of the traditional uses, phytochemistry, pharmacology, quality control and clinical applications
- 6 September 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 953, 176025
Spotlight on the accumulation of heavy metals in Traditional Chinese medicines: A holistic view of pollution status, removal strategies and prospect
- 6 September 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 953, 176025
Spotlight on the accumulation of heavy metals in Traditional Chinese medicines: A holistic view of pollution status, removal strategies and prospect
- Open Access
- 21 February 2024
- Published by Springer Nature in Chinese Medicine
- Vol. 19 (1) , 1-18
Exploring the chemical components of Kuanchang-Shu granule and its protective effects of postoperative ileus in rats by regulating AKT/HSP90AA1/eNOS pathway
Background: Postoperative ileus (POI) is a common obstruction of intestinal content passage caused by almost all abdominal operations that seriously strokes the quality of life of patients. Kuanchang-Shu granule (KCSG), a classic modified prescription based on “Da-Cheng-Qi Decoction”, has obtained satisfactory efficacy in the clinical therapeutics of POI. However, its material basis and holistic molecular mechanism against POI have not been revealed. Methods: The chemical ingredients of KCSG were first characterized by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS). Subsequently, an integration strategy of the network pharmacology and molecular docking based on above identified ingredients was performed to unveil the potential targets involved in the treatment of KCSG on POI. Finally, intestinal manipulation induced rat POI model was constructed to verify the efficacy and predicted mechanism of KCSG against POI. Results: In total, 246 ingredients mainly including organic acids, flavonoids, quinones, alkaloids, terpenoids, phenylpropanoids and phenols were identified. 41 essential ingredients, 24 crucial targets as well as 15 relevant signaling pathways were acquired based on network pharmacology analysis. Pharmacodynamic research showed that KCSG treatment could protect intestinal histological damage, promote the recovery of measurement of gastrointestinal transit disorder and inhibit the secretion of myeloperoxidase in the distal ileum tissues. The up-regulated expression of p-AKT and down-regulated expression of p-eNOS and HSP9OAA1 predicted by molecular docking and validated by western blotting showed that AKT/eNOS/HSP90AA1 pathway may be one of the crucial mechanisms that mediates the protective effect of KCSG.
- 21 February 2024
- Published by Springer Nature in Chinese Medicine
- Vol. 19 (1) , 1-18
Open AccessExploring the chemical components of Kuanchang-Shu granule and its protective effects of postoperative ileus in rats by regulating AKT/HSP90AA1/eNOS pathway
Background: Postoperative ileus (POI) is a common obstruction of intestinal content passage caused by almost all abdominal operations that seriously strokes the quality of life of patients. Kuanchang-Shu granule (KCSG), a classic modified prescription based on “Da-Cheng-Qi Decoction”, has obtained satisfactory efficacy in the clinical therapeutics of POI. However, its material basis and holistic molecular mechanism against POI have not been revealed. Methods: The chemical ingredients of KCSG were first characterized by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS). Subsequently, an integration strategy of the network pharmacology and molecular docking based on above identified ingredients was performed to unveil the potential targets involved in the treatment of KCSG on POI. Finally, intestinal manipulation induced rat POI model was constructed to verify the efficacy and predicted mechanism of KCSG against POI. Results: In total, 246 ingredients mainly including organic acids, flavonoids, quinones, alkaloids, terpenoids, phenylpropanoids and phenols were identified. 41 essential ingredients, 24 crucial targets as well as 15 relevant signaling pathways were acquired based on network pharmacology analysis. Pharmacodynamic research showed that KCSG treatment could protect intestinal histological damage, promote the recovery of measurement of gastrointestinal transit disorder and inhibit the secretion of myeloperoxidase in the distal ileum tissues. The up-regulated expression of p-AKT and down-regulated expression of p-eNOS and HSP9OAA1 predicted by molecular docking and validated by western blotting showed that AKT/eNOS/HSP90AA1 pathway may be one of the crucial mechanisms that mediates the protective effect of KCSG.